论文部分内容阅读
目的探讨肿瘤活性标志物组织多肽特异性抗原(TPS)、细胞角蛋白19片段(CYFRA211)和可溶性肿瘤坏死因子受体(STNFR)对肺癌的临床诊断价值。方法对广州军区总医院和西京医院2002～2003年72例肺癌患者、54例肺部良性疾病及32例健康人的血清TPS、CYFRA211和STNFR浓度用ELISA法进行检测。结果3种肿瘤标志物在肺癌组的水平均明显高于良性疾病组和正常对照组,且均随临床Ⅰ、Ⅱ、Ⅲ、Ⅳ期依次升高。TPS和STNFR在肺癌患者中的总阳性率(分别为80.5%和81.9%)高于CYFRA211(65.3%)。对临床Ⅰ期病人,TPS和STNFR的阳性率(分别为57.1%和57.2%)高于CYFRA211(28.6%)。结论TPS、CYFRA211和STNFR均是用于肺癌诊断的较好的肿瘤标志物,其中TPS和STNFR的临床诊断价值优于CYFRA211。
Objective To investigate the clinical diagnostic value of tumor active marker tissue-specific antigen (TPS), cytokeratin 19 (CYFRA211) and soluble tumor necrosis factor receptor (STNFR) in lung cancer. Methods Serum concentrations of TPS, CYFRA211 and STNFR in 72 patients with lung cancer, 54 patients with benign pulmonary diseases and 32 healthy persons from 2002 to 2003 in Guangzhou Military Region General Hospital and Xijing Hospital were detected by ELISA. Results The levels of three kinds of tumor markers in lung cancer group were significantly higher than those in benign disease group and normal control group, and they all increased with the clinical stages Ⅰ, Ⅱ, Ⅲ and Ⅳ. The overall positive rates of TPS and STNFR in lung cancer patients (80.5% and 81.9%, respectively) were higher than those of CYFRA211 (65.3%). The positive rates of TPS and STNFR in clinical stage I patients (57.1% and 57.2%, respectively) were higher than those of CYFRA211 (28.6%). Conclusion TPS, CYFRA211 and STNFR are both good tumor markers for the diagnosis of lung cancer. The clinical diagnostic value of TPS and STNFR is better than that of CYFRA211.